Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of BIO-TECHNE Corp (NASDAQ:TECH) by 42.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,069 shares of the biotechnology company’s stock after acquiring an additional 613 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in BIO-TECHNE were worth $268,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of the company. Aull & Monroe Investment Management Corp bought a new stake in shares of BIO-TECHNE during the 4th quarter worth approximately $214,000. SG Americas Securities LLC bought a new stake in shares of BIO-TECHNE during the 4th quarter worth approximately $1,775,000. American Capital Management Inc. lifted its holdings in shares of BIO-TECHNE by 15.9% during the 4th quarter. American Capital Management Inc. now owns 11,223 shares of the biotechnology company’s stock worth $1,454,000 after acquiring an additional 1,540 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in shares of BIO-TECHNE by 11.5% during the 4th quarter. Conestoga Capital Advisors LLC now owns 274,822 shares of the biotechnology company’s stock worth $35,603,000 after acquiring an additional 28,240 shares during the period. Finally, State of Alaska Department of Revenue lifted its holdings in shares of BIO-TECHNE by 51.1% during the 4th quarter. State of Alaska Department of Revenue now owns 9,399 shares of the biotechnology company’s stock worth $1,216,000 after acquiring an additional 3,180 shares during the period. 97.15% of the stock is owned by institutional investors.
A number of analysts have recently weighed in on TECH shares. Deutsche Bank set a $163.00 price target on shares of BIO-TECHNE and gave the stock a “buy” rating in a report on Thursday, March 1st. BidaskClub raised shares of BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Robert W. Baird upped their price target on shares of BIO-TECHNE from $154.00 to $157.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Zacks Investment Research raised shares of BIO-TECHNE from a “hold” rating to a “buy” rating and set a $145.00 price objective for the company in a research note on Wednesday, December 20th. Finally, Craig Hallum reissued a “buy” rating and issued a $160.00 price objective (up previously from $140.00) on shares of BIO-TECHNE in a research note on Wednesday, February 7th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $148.60.
In other news, Director Charles A. Dinarello sold 5,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $136.06, for a total transaction of $680,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.40% of the stock is currently owned by company insiders.
Shares of BIO-TECHNE Corp (NASDAQ:TECH) traded up $0.26 during trading hours on Wednesday, reaching $146.82. 110,886 shares of the company traded hands, compared to its average volume of 193,853. The company has a market cap of $5,500.00, a P/E ratio of 66.74, a price-to-earnings-growth ratio of 2.81 and a beta of 0.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.49 and a current ratio of 3.10. BIO-TECHNE Corp has a fifty-two week low of $98.22 and a fifty-two week high of $148.26.
BIO-TECHNE (NASDAQ:TECH) last issued its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $1.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.10. The business had revenue of $154.15 million during the quarter, compared to the consensus estimate of $145.93 million. BIO-TECHNE had a net margin of 19.17% and a return on equity of 14.39%. The firm’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.81 EPS. equities analysts predict that BIO-TECHNE Corp will post 4.01 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 2nd. Investors of record on Friday, February 16th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Thursday, February 15th. BIO-TECHNE’s payout ratio is 58.18%.
TRADEMARK VIOLATION WARNING: “Zurcher Kantonalbank Zurich Cantonalbank Has $268,000 Stake in BIO-TECHNE Corp (NASDAQ:TECH)” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://ledgergazette.com/2018/03/15/zurcher-kantonalbank-zurich-cantonalbank-buys-613-shares-of-bio-techne-corp-tech.html.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.